Antiphospholipid antibodies in patients with Graves’orbitopathy:preliminary data
Authorized Users Only
2021
Authors
Bećarević, Mirjana
Sarić-Matutinović, Marija

Žarković, Miloš
Nedeljković-Beleslin, Biljana
Ćirić, Jasmina
Ignjatović, Svetlana

Article (Published version)

Metadata
Show full item recordAbstract
Purpose: Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit and while the antiphospholipid antibodies (aPL) Abs were associated with the markers of inflammation in the antiphospholipid syndrome (APS), there is no literature that investigate the presence of aPL Abs in GO. We analyzed the prevalence of aPL Abs and the differences between aPL (+) and aPL (−) subgroups of GO patients. Methods: Study included consecutive patients with GO (66 with Graves’ (GD), 10 with Hashimoto (HD), and 8 were euthyroid). Anticardiolipin (aCL) and anti-beta 2glycoprotein I (aβ2gpI) Abs were measured by ELISA. Results: aPL Abs were present in 9/84 (10.71%) patients. The IgM aβ2gpI Abs were present in 8/66 and in 1/10 patients with GD and HD. The IgG aCL Abs were present in one GD patient, and IgM aCL were present in 3/66 GD and in 1/10 patients with HD. In GD group, anti-Tg Abs were in positive correlation with aβ2gpI IgG (p = 0.000) and with anti-TPO Abs (p = 0.016). In HD group, ...anti-Tg Abs were in positive correlation with IgM aCL (p = 0.042), while anti-TPO Abs were in positive correlation with aβ2gpI IgM (p = 0.014). Conclusion: This study is the first report of the aPL Abs presence in GO patients. The anti-thyroid Abs were linked to aPL suggesting that their presence is not the sole consequence of hyperstimulation of autoreactive B-lymphocytes. Larger studies are necessary to confirm potential cause-effect relations. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Keywords:
Antiphospholipid antibodies / Apolipoproteins / Autoimmune thyroid diseases / Graves’ orbitopathy / Interleukine 6Source:
Endocrine, 2021Publisher:
- Springer
Funding / projects:
DOI: 10.1007/s12020-021-02769-z
ISSN: 1355-008X
WoS: 000654850300001
Scopus: 2-s2.0-85106528314
Collections
Institution/Community
PharmacyTY - JOUR AU - Bećarević, Mirjana AU - Sarić-Matutinović, Marija AU - Žarković, Miloš AU - Nedeljković-Beleslin, Biljana AU - Ćirić, Jasmina AU - Ignjatović, Svetlana PY - 2021 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3909 AB - Purpose: Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit and while the antiphospholipid antibodies (aPL) Abs were associated with the markers of inflammation in the antiphospholipid syndrome (APS), there is no literature that investigate the presence of aPL Abs in GO. We analyzed the prevalence of aPL Abs and the differences between aPL (+) and aPL (−) subgroups of GO patients. Methods: Study included consecutive patients with GO (66 with Graves’ (GD), 10 with Hashimoto (HD), and 8 were euthyroid). Anticardiolipin (aCL) and anti-beta 2glycoprotein I (aβ2gpI) Abs were measured by ELISA. Results: aPL Abs were present in 9/84 (10.71%) patients. The IgM aβ2gpI Abs were present in 8/66 and in 1/10 patients with GD and HD. The IgG aCL Abs were present in one GD patient, and IgM aCL were present in 3/66 GD and in 1/10 patients with HD. In GD group, anti-Tg Abs were in positive correlation with aβ2gpI IgG (p = 0.000) and with anti-TPO Abs (p = 0.016). In HD group, anti-Tg Abs were in positive correlation with IgM aCL (p = 0.042), while anti-TPO Abs were in positive correlation with aβ2gpI IgM (p = 0.014). Conclusion: This study is the first report of the aPL Abs presence in GO patients. The anti-thyroid Abs were linked to aPL suggesting that their presence is not the sole consequence of hyperstimulation of autoreactive B-lymphocytes. Larger studies are necessary to confirm potential cause-effect relations. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. PB - Springer T2 - Endocrine T1 - Antiphospholipid antibodies in patients with Graves’orbitopathy:preliminary data DO - 10.1007/s12020-021-02769-z ER -
@article{ author = "Bećarević, Mirjana and Sarić-Matutinović, Marija and Žarković, Miloš and Nedeljković-Beleslin, Biljana and Ćirić, Jasmina and Ignjatović, Svetlana", year = "2021", abstract = "Purpose: Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder of the orbit and while the antiphospholipid antibodies (aPL) Abs were associated with the markers of inflammation in the antiphospholipid syndrome (APS), there is no literature that investigate the presence of aPL Abs in GO. We analyzed the prevalence of aPL Abs and the differences between aPL (+) and aPL (−) subgroups of GO patients. Methods: Study included consecutive patients with GO (66 with Graves’ (GD), 10 with Hashimoto (HD), and 8 were euthyroid). Anticardiolipin (aCL) and anti-beta 2glycoprotein I (aβ2gpI) Abs were measured by ELISA. Results: aPL Abs were present in 9/84 (10.71%) patients. The IgM aβ2gpI Abs were present in 8/66 and in 1/10 patients with GD and HD. The IgG aCL Abs were present in one GD patient, and IgM aCL were present in 3/66 GD and in 1/10 patients with HD. In GD group, anti-Tg Abs were in positive correlation with aβ2gpI IgG (p = 0.000) and with anti-TPO Abs (p = 0.016). In HD group, anti-Tg Abs were in positive correlation with IgM aCL (p = 0.042), while anti-TPO Abs were in positive correlation with aβ2gpI IgM (p = 0.014). Conclusion: This study is the first report of the aPL Abs presence in GO patients. The anti-thyroid Abs were linked to aPL suggesting that their presence is not the sole consequence of hyperstimulation of autoreactive B-lymphocytes. Larger studies are necessary to confirm potential cause-effect relations. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.", publisher = "Springer", journal = "Endocrine", title = "Antiphospholipid antibodies in patients with Graves’orbitopathy:preliminary data", doi = "10.1007/s12020-021-02769-z" }
Bećarević, M., Sarić-Matutinović, M., Žarković, M., Nedeljković-Beleslin, B., Ćirić, J.,& Ignjatović, S.. (2021). Antiphospholipid antibodies in patients with Graves’orbitopathy:preliminary data. in Endocrine Springer.. https://doi.org/10.1007/s12020-021-02769-z
Bećarević M, Sarić-Matutinović M, Žarković M, Nedeljković-Beleslin B, Ćirić J, Ignjatović S. Antiphospholipid antibodies in patients with Graves’orbitopathy:preliminary data. in Endocrine. 2021;. doi:10.1007/s12020-021-02769-z .
Bećarević, Mirjana, Sarić-Matutinović, Marija, Žarković, Miloš, Nedeljković-Beleslin, Biljana, Ćirić, Jasmina, Ignjatović, Svetlana, "Antiphospholipid antibodies in patients with Graves’orbitopathy:preliminary data" in Endocrine (2021), https://doi.org/10.1007/s12020-021-02769-z . .